Consumer Health + Drug Discovery
AI + Real World Evidence

Led by an experienced scientific and executive team, BluMaiden will transform consumer healthcare and patient treatment through large-scale data capture, AI powered investigation of metagenomes and synthetic biology methodologies all in our expertise of microbiome and health sciences.

Our Expert Network

In addition to our core team in Singapore, we are backed by an ever-expanding expert network across the global. Supported by their talents and insights in data science, technology, IT, healthcare, marketing, branding, and sales, we are co-developing key projects for R&D, Business and Marketing.

 

Embracing Diversity

Diverse and inclusive teams have a positive impact on our products and services, and help us better serve customers, selling partners, content creators, employees, and community stakeholders from every background. We are constantly learning and iterating, whether through central programs, or work within our business teams, through programs that are local, regional, and global. BluMaiden Biosciences are aware that our current team composition does not fulfil our diversity goals. As an early company securing expertise and moving the business plan forward fast are important drivers. We are actively recruiting for diverse candidates to fill many board and senior positions.

Board of Directors

Michael Tillman  
Chairman

Mr. Tillmann is a seasoned CEO, board member and entrepreneur with 30 years of experience in the pharmaceutical and diagnostics industry. Mr. Tillmann has a stellar 30-year track-record in the pharmaceutical and diagnostics industry.

Terence A. Kelly, Ph.D
Director

Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is expert in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development.

Robert Meyer
Director

Robert is the founder and Managing Partner of Angsana Investments Pte Ltd, a private venture firm that is focussed on direct investments in early-stage opportunities.

Damien Keogh, Ph. D
Director

Dr. Keogh is the Chief Executive Officer and Founding Member of BluMaiden Biosciences. He has assembled the founding team and recruited a distinguished Board of Directors and Scientific Advisors. Dr. Damien Keogh is a data-driven and innovative scientist with a background in biotechnology, commercialization, and entrepreneurship. Following undergraduate studies in Biotechnology he obtained a PhD in Microbiology

Scientific Advisory Board

Damian O’Connell, Ph.D
Scientific Advisory Board, Member

Professor Damian O’Connell is Chief Executive Officer the Experimental Drug Development Centre at A*Star – the Agency for Science, Technology and Research based in Singapore. The Experimental Drug Development Centre is a national platform for drug and biomarker discovery as well as early clinical development.

Kim Lewis, Ph.D        Scientific Advisory Board, Member

Professor Kim Lewis is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is a University Distinguished Professor and the Director of Antimicrobial Discovery Center at Northeastern University in Boston, Massachusetts.

Nicholas Talley, Ph.D
Scientific Advisory Board, Member

Distinguished Laureate Professor Nicholas Talley AC is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is based at the University of Newcastle, Australia and held former appointments as Chair of the Department of Internal Medicine at Mayo Clinic in Jacksonville, Florida, a Professor of Medicine and Professor of Epidemiology at Mayo Clinic and Foundation Professor of Medicine at the University of Sydney, Nepean Hospital.

Stephen Simpson, Ph.D
Scientific Advisory Board, Member

Professor Stephen Simpson, FRS is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is the Director of the Charles Perkin Centre at the University of Sydney, a Professor in the School of Life and Environmental Sciences at the University of Sydney, and Executive Director of Obesity Australia

Founding Members

Damien Keogh, Ph. D
Chief Executive Officer

Dr. Keogh is the Chief Executive Officer and Founding Member of BluMaiden Biosciences. He has assembled the founding team and recruited a distinguished Board of Directors and Scientific Advisors. Damien Keogh is a data-driven and innovative scientist with a background in biotechnology, commercialization, and entrepreneurship. Following undergraduate studies in Biotechnology he obtained a PhD in Microbiology (DCU Dublin, Ireland) with a specialization in metabolite biology and microbial-host interactions.

Rohan Williams, Ph. D
Chair of SAB, Computational Bio Expert

Rohan Williams is a computational biologist, specialising in bioinformatics and systems biology of microbiomes and microbial ecology. Following undergraduate studies in Physics he obtained a PhD in Medicine at the University of New South Wales (Sydney, Australia) in the field of human gastrointestinal physiology

Peter K. Ellegaard
General Counsel

Peter Kristian Ellegaard is the General Counsel of BluMaiden Biosciences Pte Ltd.  In this role, Peter leads the company’s global legal, regulatory, compliance and corporate secretary functions. 

Robert Meyer 
Director

Robert is the founder and Managing Partner of Angsana Investments Pte Ltd, a private venture firm that is focussed on direct investments in early-stage opportunities.

Scientific and Business Development Team

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Executive Team

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Damien Keogh
CEO

Damien enter bio here Lorem ipsum dolor sit amet, consectetur adipiscing elit, set doeiusmod tempor incididunt ut labore et dolore magna aliqua. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur except.

Our Vision And Mission

Unlocking the potential of

human microbiome with deep tech

The answer to human health lies within our own body. The commensal microbiome has co-evolved with human populations through millennia and has developed powerful ways to regulate human health through secreted signaling molecules. This reservoir of signaling molecules, naturally found and working in our own bodies, offers a safer and more efficient way to improve health, but remains largely untapped. Backed by our investors, advisory boards and partners, the BluMaiden team is on a mission to uncover the intricate connection between microbiome signals and human health for the development of drugs, diagnostics and consumer health technologies.

Unlocking the potential of human microbiome with deep tech

The answer to human health lies within our own body. The human microbiome has co-evolved with human populations through millennia and has developed powerful ways to regulate human health through secreted signaling molecules. This reservoir of microbiome-derived compounds, naturally found and working in our own bodies, offers a safer and more efficient way to improve health, but remains largely untapped. Backed by our investors, advisory boards and partners, the BluMaiden team is on a mission to uncover the intricate connection between microbiome signals and human health for the development of therapeutics, diagnostics and consumer health technologies.

Our Values

1. Pioneering Spirit

+ We venture beyond boundaries to tackle unmet needs in new ways

+ Dare to think differently to change the status quo

+ Innovative integrated platform technology and analytics streamlines the road to drug discovery.

2. Holistic Point of View

+ Big picture thinkers who invest in the outcomes

+ We’ve integrated data capture, analysis, and discovery for a seamless drug discovery process

+ Seek partnerships and effective co-creation with consumers and pharma companies

3. Uphold Excellence

+ Pursue a high level of intellectual and scientific rigor

+ Welcome obstacles and challenges as opportunities to improve and innovate

+ We invest in people, the foundation of an enduring company

4. Do Right

We own our actions

+ Act with conviction, compassion and empathy

+ Uphold a high ethical conduct in our research and process

+ Dedicated to the science and better outcomes for all

Code of Conduct

We strongly believe that compliance & ethics are essential to preserve and strengthen the trust of our patients, business partners, shareholders and communities. We ensure transparency in all aspects of our business operation, conduct ourselves at all times in accordance with our vision and values as outlined in our Code of Conduct, and hold ourselves accountable for meeting the expectations we place on ourselves.

Get In Touch

If any of what we do resonates with you, whether you are a medical practitioner, a patient, a researcher, an investor, a potential partner or would like to learn more about our science and technology, reach out to us.

Michael Tillmann
Chairman

Mr. Tillmann is a seasoned CEO, board member and entrepreneur with 30 years of experience in the pharmaceutical and diagnostics industry. Mr. Tillmann has a stellar 30-year track-record in the pharmaceutical and diagnostics industry. Having served Roche Diagnostics as its Asia Pacific and North America CEO with a seat in the Roche Global Executive Board, Mr. Tillmann has been running his own bio-tech incubator Amatar Group since 2010. In this role, he also founded Vela Diagnostics Ltd, which was acquired by the Luye Lifescience Group in 2020. Mr. Tillmann sits in multiple supervisory & advisory boards. Additionally, he supports companies in their strategic positioning and M&A activities, where he advised in his latest project AmpTec GmbH, which was acquired by Merck KGaA, Germany.

Terence A. Kelly, Ph. D
Director

Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is expert in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development.
Between 1990 and 2009, Terry served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department.  From 2010 – 2016 he was the CEO and CSO of CoMentis, Inc, a venture-backed biotech focusing on treating cognitive disorders.  He is a founder of Kelly Pharma Research Consulting, LLC and has served as a director of Cardax, Inc. since June 2014. Terry is currently the President and CEO of Perception Neuroscience, a clinical stage biotech company developing small molecule therapeutics for mental health disorders.
Terry holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute and a Ph.D. degree in Chemistry at the University of Texas at Austin. He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University. Dr. Kelly is the co-author of over 25 scientific publications and served on the College of Natural Sciences Advisory Council for the University of Texas.

Robert Meyer
Director

Robert is the founder and Managing Partner of Angsana Investments Pte Ltd, a private venture firm that is focussed on direct investments in early-stage opportunities.

Robert is also the CEO of Caber Partners Pte Ltd, an Alternative Asset Manager licensed by the Monetary Authority of Singapore (MAS) as Fund Manager and Exempt Financial Advisor. In June 2021, Caber launched the Angsana Natural Rubber Opportunities Fund I (“ANRO”), a macro hedge fund that positions in rubber futures and derivatives.

Prior to launching Angsana, Robert co-founded SGX-listed Halcyon Agri Corporation Limited and served as its CEO from January 2013 to June 2020.

During his tenure, Halcyon Agri executed a buy-and-build roll-up strategy to create the world’s largest rubber franchise. In 2016, Halcyon Agri acquired the natural rubber business of Chinese state-owned Sinochem International Limited in a landmark transaction that valued the enlarged group at USD800m. At Halcyon Agri, Robert also initiated the launch of HeveaConnect, the world’s first digital marketplace for sustainable natural rubber, in partnership with Itochu Corporation and DBS Bank Limited and, most recently, SGX.

Robert has a keen interest in geopolitics and served on Singapore’s Economic Strategies Committee (ESC) in 2010. Presently, Robert is a member of the National University of Singapore Health International Council (NIC).

Damien Keogh, Ph.D
Chief Executive Officer

Dr. Keogh is the Chief Executive Officer and Founding Member of BluMaiden Biosciences. He has assembled the founding team and recruited a distinguished Board of Directors and Scientific Advisors. Dr. Damien Keogh is a data-driven and innovative scientist with a background in biotechnology, commercialization, and entrepreneurship. Following undergraduate studies in Biotechnology he obtained a PhD in Microbiology (DCU Dublin, Ireland) with a specialization in metabolite biology and microbial-host interactions. His early postdoctoral work was sponsored by the Pharmaceutical company Bristol Myers Squibbs Ltd. with the aim of developing molecular tools to enhance drug purification.

He served the Department of Biotechnology at DCU as a lecturer in molecular biology for a number of years while his R&D activities contributed to the spin-out of a biotech company generating novel glycoselective bioaffinity compounds for the detection, analysis, separation, and purification of glycosylated biomolecules. In 2013 Dr. Keogh began work at the Singapore Centre for Environmental Life Sciences Engineering (SCELSE), a Research Centre of Excellence co-hosted by the National University of Singapore and Nanyang Technological University. He developed new methods and insights to polymicrobial host infection, biofilm dynamics, and antimicrobial efficacy.

In 2017, he moved to a Venture Capital firm as an Entrepreneur-in-Residence providing domain expertise in microbiology. From here, he continued his entrepreneurial drive with biotech endeavors in healthcare and therapeutics domains and became an alumni of Johnson & Johnson Innovation JLABS. He holds diverse perspectives from working in academia, venture capital, and start-up companies. 

Damian O’Connell, Ph. D
Scientific Advisory Board, Member

Prof Damian O’Connell is Chief Executive Officer the Experimental Drug Development Centre at A*Star – the Agency for Science, Technology and Research based in Singapore. The Experimental Drug Development Centre is a national platform for drug and biomarker discovery as well as early clinical development.

Most recently Damian was Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG, Berlin – Germany. Prof O’Connell previously held senior positions within Pfizer Research & Development, Parke Davis, Elan Pharmaceuticals and Neurex. Prof O’Connell has both MD & PhD degrees from the National University of Ireland, has been a Medical Faculty member of the University of Virginia Health Sciences Center as well as a member of the Clinical Pharmacology & Therapeutics Department at the University College Cork, Ireland where he was a Professor of Clinical Research. He started his career in the Industry in 1998.

Prof O’Connell is an Adjunct Professor at University College Cork, Ireland; Member Expert Advisory Panel, Singapore Translational Cancer Consortium;  Member Advisory Board Investigational Medicine Unit SingHealth, Singapore; Board Member INFANT Research Centre, Cork Ireland; Member Scientific Advisory Board, BluMaiden Biosciences, Singapore; Member of the Faculty of Pharmaceutical Medicine; Fellow of The Royal Society of Medicine; Fellow of The Royal Academy of Medicine (Ireland); Member of the British Pharmacological Society; Member of the Drug Safety Executive Council (DSEC); Member American Society for Clinical Pharmacology and Therapeutics; Member American College of Clinical Pharmacology.

Kim Lewis, Ph. D
Scientific Advisory Board, Member

Professor Kim Lewis – Professor Kim Lewis is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is a University Distinguished Professor and the Director of Antimicrobial Discovery Center at Northeastern University in Boston, Massachusetts. Formally he held faculty appointments at Massachusetts Institute of Technology, University of Maryland and Tufts University. A distinguished molecular microbiologist whose research career has focused on the mechanisms of antimicrobial resistance, Lewis is a Fellow of the American Association for the Advancement of Science and a Fellow of the American Academy of Microbiology.

Lewis’ research has resolved key problems underpinning the mechanisms by which bacteria can resist the action of antibiotics, discovered new classes of antibiotics and demonstrated the potential of finding antibiotic compounds in microbiomes. Lewis has a long-standing engagement with the biotech industry and pharma. At BluMaiden Biosciences, he is guiding the scientific team on approaches for discovering new therapeutic compounds from human microbiomes.

Nicholas Talley, Ph. D
Scientific Advisory Board, Member

Distinguished Laureate Professor Nicholas Talley AC is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is based at the University of Newcastle, Australia and held former appointments as Chair of the Department of Internal Medicine at Mayo Clinic in Jacksonville, Florida, a Professor of Medicine and Professor of Epidemiology at Mayo Clinic and Foundation Professor of Medicine at the University of Sydney, Nepean Hospital.

Professor Talley is considered one of the world’s leading authorities in diseases of the upper and lower gastrointestinal tract. Among other advances, his research has documented genetic determinants of irritable bowel syndrome (IBS), and the role of the immune system and gut microbiota in functional gastrointestinal disease. At BluMaiden Biosciences, he is guiding the scientific team as they develop pioneering solutions to human microbiome associated diseases.,

Stephen Simpson, FRS, Ph. D
Scientific Advisory Board, Member

Professor Stephen Simpson, FRS is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is the Director of the Charles Perkin Centre at the University of Sydney, a Professor in the School of Life and Environmental Sciences at the University of Sydney, and Executive Director of Obesity Australia. Prior to his current appointments, Simpson was at the University of Oxford for over 20 years. In 2013 he was elected a Fellow of the Royal Society of London as “one of the world’s foremost entomologists and nutritional biologists”.

Simpson is a highly innovative thinker in nutritional science, having developed new measurement and modelling frameworks for studying nutritional intake behaviours in a range of organisms, including humans. This approach, termed nutritional ecology, draws on ecology and evolutionary theory to provide a new foundation for thinking about human nutrition. At BluMaiden Biosciences, he is guiding the scientific team in their attempts to build a platform for microbiome-enabled personalized nutrition.

Rohan Williams, Ph.D
Chair of SAB, Computational Bio Expert

Rohan Williams is a computational biologist, specialising in bioinformatics and systems biology of microbiomes and microbial ecology. Following undergraduate studies in Physics he obtained a PhD in Medicine at the University of New South Wales (Sydney, Australia) in the field of human gastrointestinal physiology, and undertook postdoctoral work in computational genetics and genomics, before obtaining an academic appointment at the John Curtin School of Medical Research, Australian National University, Canberra in 2007.

He relocated to Singapore in 2011 to commence as a principal investigator of the Singapore Centre for Environmental Life Sciences Engineering (SCELSE), a Research Centre of Excellence co-hosted by the National University of Singapore and Nanyang Technological University, where he is the Head of the SCELSE Integrative Analysis Unit. At SCELSE he and his research group develop new methods for analysing the composition and function of microbiomes, with particular focus on the use of long read sequencing technology and multi-omics.

Williams holds diverse research perspectives from this experience working in basic, clinical and environmental settings, including collaborations with two multinational companies and government agencies. He has published around 80 research papers, review articles and book chapters.

Peter K. Ellegaard    
General Counsel

Peter Kristian Ellegaard is the General Counsel of BluMaiden Biosciences Pte Ltd.  In this role, Peter leads the company’s global legal, regulatory, compliance and corporate secretary functions.

Earlier in his career, Peter served with multinational corporations, including Maersk, in senior legal, compliance and business leadership roles.  He was previously an M&A attorney with Morgan, Lewis & Bockius LLP in New York where he advised on several life sciences transactions, including a USD 1bn pharmaceutical acquisition of the Johnson & Johnson professional wound care business operations in 50 jurisdictions for JPMorgan.

Peter’s compliance and ethics expertise includes developing global and regional compliance strategies, codes of conduct, policies and training materials as well as leading, managing and conducting investigations into allegations of fraud, corruption and other misconduct in a multitude of jurisdictions.  In his previous roles with listed companies, he also had oversight of securities laws and risk management compliance.

Peter is admitted to practice in the State of New York as an attorney and counselor-at-law, to the roll of solicitors of the Senior Courts in England and Wales (currently inactive) and as an advocate in Denmark (currently inactive).  He is also admitted to appear before the United States District Court for the Southern District of New York.  

Peter received his LL.M. from Fordham University School of Law in 2007.  He received his LL.M. in Danish law in 2002 and his LL.B. in 2001 from the University of Copenhagen, Denmark and his B.Comm. with majors in accounting and finance in 1997 from Flinders University of South Australia.  He also holds a Postgraduate Diploma in Maritime Law (master’s level) from London Metropolitan University.